Изучение роли филаггрина в патогенезе атопического дерматита при беременности

Abstract

The aim of the research. To study the role of fi laggrin protein in pathogenesis of atopic dermatitis (AD) exacerbation during gestation and to evaluate the effectiveness of the “emollient + topical antipruritic agent” combination therapy. Material and methods. A total of 110 female patients were examined. Among them, 70 were pregnant women with exacerbation of AD, 20 were non-pregnant women with AD exacerbation and 20 were healthy pregnant women. The AD severity was assessed using a point scale – the SCORAD index. Pruritus characterisation was performed using the 5-D Itch Scale by Elman. The serum filaggrin protein level was measured by ELISA. The efficacy of the combination therapy was assessed aft er treatment and included evaluation of AD severity, pruritus, and filaggrin protein levels. Statistical processing of the results was carried out using the Statistica 6.0 application soft ware package. Results. As the result of the study, it was found that the serum filaggrin level was higher in pregnant women with exacerbated AD than in the group of non-pregnant women with exacerbated AD (Mann-Whitney test, p = 0.007) and healthy pregnant women (Mann-Whitney test, p = 0.001). Filaggrin levels decreased after combination therapy. Pruritus evaluation revealed no significant difference between the groups with exacerbated AD (Mann-Whitney test, p = 0.221). After treatment, a significant decrease (Mann-Whitney test, p = 0,001) in itching was noted in the group of pregnant women with AD exacerbation. The mean value of the SCORAD index before and after treatment in the group of pregnant women with AD decreased significantly (Mann-Whitney test, p = 0.001). Conclusion. According to the data obtained, the level of filaggrin in pregnant women with exacerbation of AD is significantly higher than in the control groups. Against the background of combination therapy, there is positive dynamics of the clinical course of AD, as well as a decrease in the level of filaggrin in the blood serum. Further research in this area is required.